Breakthrough invasive aspergillosis in allogeneic haematopoietic  stem cell transplant recipients treated with caspofungin.
During the period January 2004 to April 2007, nine cases of breakthrough invasive aspergillosis occurred among 156 allogeneic haematopoietic stem cell transplant recipients receiving caspofungin therapy, mainly for empirical treatment of persisting fever. Voriconazole salvage therapy induced two complete responses. However, seven patients ultimately died a median of 5 weeks after diagnosis, including five patients with aspergillosis. This high incidence of breakthrough invasive aspergillosis in this patient population receiving caspofungin therapy warrants further investigation.
Madureira
Adrienne
A
Hematology-Bone Marrow Transplant Unit, Saint-Louis Hospital, Université Paris VII, 1 avenue Claude Vellefaux, 75010 Paris, France.
Bergeron
Anne
A
Lacroix
Claire
C
Robin
Marie
M
Rocha
Vanderson
V
de Latour
Régis Peffault
RP
Ferry
Christèle
C
Devergie
Agnès
A
Lapalu
Jordane
J
Gluckmana
Eliane
E
Socié
Gérard
G
Ghannoum
Mahmoud
M
Ribaud
Patricia
P
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000382:microbiology / Q000401:mortality / Q000517:prevention & control*; D001230:Aspergillus / Q000187:drug effects*; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D055666:Lipopeptides; D011743:Pyrimidines / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000009:adverse effects*; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; D000077336:Caspofungin; D065819:Voriconazole